Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Abstract

This case series underscores the value of targeted immunotherapy in treating angiosarcoma. It also identifies genetic heterogeneity of cutaneous angiosarcomas and discusses specific genetic findings that may explain reported benefits from immunotherapy.